132.1 ð é«åžçç
132.1.0.1 ð äžé éé»
- ç å : å€ aspiration of oropharyngeal flora (anaerobes); 2nd: bronchial obstruction (cancer, foreign body), septic embolism (IVDU, IE), bacteremia
- ç å: anaerobes (Bacteroides, Prevotella, Fusobacterium, Peptostreptococcus); aerobes (S. aureus, K. pneumoniae, Streptococcus); å ç«äœäž (Pseudomonas, Aspergillus, Nocardia, fungi, mycobacteria)
- ç¹åŸµ: insidious 1-3 é±çŒå±; foul-sputum (anaerobes); cavity > 2 cm with air-fluid level on CXR/CT
- æ²»ç: 4-6 é± antibiotic (longer if large/complex); first-line: amoxicillin-clavulanate OR clindamycin; surgical drainage rarelyéèŠ (90% medical management å³å¯)
132.1.0.2 1ïžâ£ ç å åé¡
132.1.0.2.1 A. Primary (Aspiration)
- æåžžèŠ (70-80%)
- Risk: æèäžé (alcohol, drug, seizure, anesthesia), dysphagia (stroke, dementia, esophageal disease), poor dental hygiene, GERD
- äœçœ®: äŸ aspiration position
- è¥å§¿ (supine): äžè posterior + äžè superior segments
- çŽç«: lower lobes basal segments
- å³èºå€ (right main bronchus èŒçŽ)
132.1.0.3 2ïžâ£ èšåºè¡šçŸ
- Insidious: weeks of fever, cough, weight loss, night sweats
- Foul-smelling sputum (anaerobic â pathognomonic)
- ç°æ¶² putrid, may be hemoptysis
- Halitosis
- Clubbing (chronic)
- Examination: amphoric breath sounds over cavity (if > 4 cm)
132.1.0.4 3ïžâ£ 蚺æ·
132.1.0.4.1 CXR / CT
- CXR: cavity ⥠2 cm with air-fluid level
- CT: better â defines size, cavity wall, air-fluid level, surrounding parenchyma, bronchial obstruction (mass), associated lymphadenopathy
132.1.0.5 4ïžâ£ æ²»ç
ð äžææŠå¿µèªªæïŒèºè¿ç幟ä¹éœé antibiotic + bronchoscopy 解決ïŒå€ç§ < 10%ãèšåºæ±ºçäžéµåïŒ(1) ççšè³å° 4-6 é±ïŒå€ªçæåŸ©çŒïŒ(2) 远 serial CXR ç air-fluid level æ¶å€± (cavity æ®ç坿¥å)ïŒ(3) åŠæ 6 鱿²»ç倱æ â äžå®èŠæé€ bronchial obstruction (CT + bronchoscopy) â cancer æ foreign body äžè§£é€ïŒè¿çäžæå¥œãMetronidazole äžå¯å®çšäœ¿ç𠿝åèé«é »é·é±é¡ â å° microaerophilic Streptococcus ç¡æïŒå¿ é è β-lactam åçšæçš ampicillin-sulbactam / amox-clav å代ã
132.1.0.5.1 Antibiotic (medical, 90% sufficient)
| åŽé床 | æ²»ç |
|---|---|
| Mild-moderate, primary | Amoxicillin-clavulanate 875/125 BID PO Ã 4-6 wk |
| OR | Clindamycin 600 mg IV q8h â 300 mg PO QID Ã 4-6 wk |
| Hospitalized / severe | Ampicillin-sulbactam 3g IV q6h OR Pip-tazo OR Carbapenem + èæ ® vanco/linezolid (MRSA risk) |
| Specific / failed empirical | adjust per culture; long course |
â ïž Metronidazole alone äžå€ â äžå° microaerophilic Streptococcus
132.1.0.5.2 Duration
- 4-6 鱿å°
- è¥ large > 6 cm, å€ cavity, immunocompromised â 2-3 months
- Resolution monitor with serial CXR (no air-fluid level â æ²»çæå)
- Cavity may persist (residual) â äžå¿ å»¶é· antibiotic if clinically improved
132.1.0.5.3 Surgical / Procedural
- å€§å€ äžéèŠ surgical drainage
- Indications: æ²»ç 6 é±å€±æãå·šå abscess > 8 cm æçº, åŽé hemoptysis, æ²»çåæå·®, malignant component
- Percutaneous drainage (CT-guided): for large/peripheral
- Surgical resection (lobectomy): rare; reserved for refractory